Skip to main content

Precision health perspectives

By Carousel Slider, Commentary, In the News
Leslie Thompson discusses how UCI’s collaborative approach can help usher in the next great advancement in healthcare July 11, 2022 “I’ve been involved in many very meaningful research projects in my career, but to be perfectly honest, this is huge for me, as I feel it ultimately can help the families that I so passionately care about,” says Leslie Thompson. Steve Zylius / UCI In February, UCI launched the Institute for Precision Health, a campus-wide, interdisciplinary endeavor that merges UCI’s powerhouse health sciences, engineering, machine learning, artificial intelligence, clinical genomics and data science capabilities. The objective is to identify, create…
Read More

Research reveals how brain inflammation may link Alzheimer’s risk, sleep disturbance

By Carousel Slider, Commentary, In the News
Multisite team included UCI, University of Wisconsin–Madison, Wake Forest University July 13, 2022 “Our findings indicate that age-related increases in brain inflammation have a downstream effect on Alzheimer’s disease-related tau proteins and neuronal synaptic integrity,” says Bryce Mander, Ph.D., UCI assistant professor of psychiatry & human behavior and the study’s lead and co-corresponding author. “This results in deficits in the brain’s capacity to generate fast sleep spindles, which contribute to age-related memory impairment in older adults.” UCI School of Medicine Irvine, Calif., July 13, 2022 – A multisite research team from the University of California, Irvine, the University of Wisconsin–Madison and…
Read More

Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers

By Carousel Slider, Commentary, In the News
Contributed by Mark Mapstone, PhD UCI MIND faculty Mark Mapstone, PhD and Ira Lott, MD collaborated on research that was recently published in JAMA Neurology. Learn more about their findings: Studying Alzheimer’s disease in people with Down syndrome is a very important avenue for research because nearly all people with Down syndrome will develop the brain changes of Alzheimer’s disease. These changes include the abnormal accumulation of two proteins; amyloid and tau. In this study, we wanted to know if we could measure these changes in blood and if these changes accurately reflect the changes happening in the brain.  We…
Read More

Doctors and researchers encourage people to be mindful of their brain health

By Carousel Slider, Commentary, In the News
DOTHAN, Ala. (WTVY) - Alzheimer’s and Dementia affect millions of people worldwide. Changes in the brains of people with the disease can start decades before the person actually experiences symptoms, that’s according to the AHEAD Study. With June being Alzheimer’s and Brain Awareness month, doctors and researchers of the AHEAD study are urging people to be conscious about their health and their loved ones. Doctor Josh Grill, a University of California Irvine professor, shares tips to improve and become mindful of your brain health. He said taking part in physical exercise, eating a healthy diet, getting a good night’s sleep…
Read More

How exercise may help prevent Alzheimer’s

By Carousel Slider, Commentary, In the News
Image Credit: David Tett via Centre for Ageing Better Exercise could be a powerful defense against Alzheimer’s disease. Three dementia researchers explain how it works. NOVA - When it comes to dementia prevention, sleep and exercise may work together, says neuroscientist Miranda Chappel-Farley, a Ph.D. candidate at University of California, Irvine. … Together, they create a powerful bulwark against dementia and represent a lifestyle factor ignored at your peril, says Chappel-Farley, who cautions against “targeting exercise but not paying attention to sleep.” Read more here >
Read More

New treatments for psychosis in Alzheimer’s disease – pimavanserin and the FDA, redux

By Carousel Slider, Commentary, In the News
Contributed by David Sultzer, MD and Joshua Grill, PhD An FDA Advisory Committee met on June 17 to provide input to the Agency regarding the effectiveness of pimavanserin for the treatment of psychosis in Alzheimer’s disease.  The Committee voted 9 to 3, with the majority finding insufficient evidence of effectiveness in this population. This input comes on the heels of an FDA review last year that declined to approve pimavanserin for psychosis in a broad group of dementia syndromes, including Alzheimer’s disease, vascular dementia, Lewy body and Parkinson’s disease dementia, and frontotemporal dementias.  At that time, the Agency felt that…
Read More

UCI researchers aim to diversify clinical research participation with $3.7 million NIH grant

By Carousel Slider, Commentary, In the News
The multidisciplinary team will focus on participant recruitment and retainment for Alzheimer’s disease and related disorders research Josh Grill, left, and Daniel Gillen will examine what role recruitment registries for ADRD research can play in overcoming exclusions to improve research outcomes. What is the best way to recruit participants to join a clinical studies registry, and can such registries help better diversify clinical research samples? These are two critical questions that UCI researchers are tackling with a new National Institutes of Health grant, “Recruiting and Retaining Participants from Disadvantaged Neighborhoods in Registries.” The work will be led by Joshua Grill, professor…
Read More

UCI wins 5-year, $14M NIH grant to study brain circuits susceptible to aging, Alzheimer’s disease

By Carousel Slider, Commentary, In the News
Findings will advance development of better early diagnostic tools, new treatment strategies “This project will capture a composite of disease features to expand our understanding of the brain circuits susceptible to aging and Alzheimer’s. Our findings will facilitate the development of more effective early diagnostic tools and the discovery of new therapies,” says UCI’s Xiangmin Xu. Steve Zylius / UCI The University of California, Irvine has been awarded a five-year, $14 million grant from the National Institutes of Health to study brain circuits that are susceptible to aging and Alzheimer’s disease. The research findings will advance the development of early…
Read More

UCI MIND and UPENN Colleagues offer new guidance

By Carousel Slider, Commentary, In the News
In a blunt rejection of current norms, two leaders of biomarker disclosure research argue research participants should have the opportunity to know whether they have biomarkers of Alzheimer’s disease . Biomarkers, or biological indicators of a disease, are essential to the study and diagnosis of Alzheimer’s and other diseases that cause dementia. Clinicians use imaging such as MRI and PET scans to measure biomarkers and make accurate diagnoses. Blood tests are fast becoming available too. The tests also allow researchers to develop targeted drug therapies. But in both clinical care and research, biomarker results are infrequently disclosed. Insurers typically do…
Read More